Cipla has entered into a strategic distribution, supply and development agreement with the US-based BioQ Pharma for registration and commercialisation of the latter’s Ropivacaine infusion system, used in treating post-operative pain, in India.
The Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQ Pharma’s unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.
Cipla’s proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma’s proprietary unit-dose, large volume infusion pharmaceuticals to India’s healthcare market.
